Back to Search Start Over

Isn't it time to consider oncological status as a new risk factor of iodinated contrastdia hypersensitivity?

Authors :
UCL - (SLuc) Service de pneumologie
UCL - (SLuc) Centre de l'allergie
UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie
Dellis, Perrine
Pirson, Françoise
UCL - (SLuc) Service de pneumologie
UCL - (SLuc) Centre de l'allergie
UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie
Dellis, Perrine
Pirson, Françoise
Source :
European annals of allergy and clinical immunology, Vol. 54, no. 02, p. 68-76 (2022)
Publication Year :
2022

Abstract

Background: The literature describes several risk factors for hypersensitivity (HS) reactions to iodinated contrast media (ICM). Objective: To analyze the characteristics of patients experiencing HS reactions to ICM with a focus on oncological status. Methods: All patients (n=80) with suspected HS to ICM who underwent an allergy evaluation in a Belgian University Hospital over a 5-year period were retrospectively included. Results: Overall, forty patients (50%) had a history of neoplasia, and this group was characterized by less atopy (p<0.004). No significant difference was observed between oncological and non-oncological patients in terms of gender, age, cardiovascular diseases, medical treatment, and number of previous exposures or reactions to ICM. Conclusion: A high proportion of oncological patients was observed in our population with HS to ICM. They did not have other known risk factors, and they were less atopic. Larger multicentric studies should explore cancer as a potential new risk factor.

Details

Database :
OAIster
Journal :
European annals of allergy and clinical immunology, Vol. 54, no. 02, p. 68-76 (2022)
Notes :
English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1372955465
Document Type :
Electronic Resource